Corcept therapeutics inc (CORT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities:
Net income

94,181

75,410

129,122

8,140

-6,408

-31,383

-46,011

-38,048

Adjustments to reconcile net income to net cash generated from operations:
Stock-based compensation

29,313

23,747

13,361

7,058

6,013

5,201

5,196

5,310

Accretion of interest expense

-

-

-

-

2,848

3,678

4,410

1,680

Depreciation and amortization of property and equipment

0

0

14

21

22

29

35

17

Deferred income taxes

16,877

14,067

-76,703

0

0

-

-

-

Accretion of interest income

-1,738

-1,721

456

1,929

-

-

-

-

Deferred income taxes

0

0

-293

0

0

-

-

-

Depreciation and amortization of property and equipment

703

236

106

87

155

141

74

27

Non-cash amortization of right-of-use asset

1,468

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables

2,340

2,288

5,440

3,639

2,887

1,906

871

557

Other receivable

0

-12,896

12,896

0

0

-

-

-

Inventory

1,044

7,779

2,262

682

-815

-249

883

4,663

Prepaid expenses and other current assets

-1,696

5,071

705

1,322

-799

531

290

480

Other assets

3,398

0

26

0

7

-10

4

-11

Accounts payable

-735

-389

6,289

965

-561

-495

-1,423

193

Accrued clinical expenses

2,956

1,274

780

296

835

-2,952

2,445

199

Accrued and other liabilities

-517

5,044

8,546

5,696

1,381

575

255

275

Long-term accrued income taxes

147

239

0

0

-

-

-

-

Operating lease liabilities

-1,452

0

0

-

-

-

-

-

Deferred revenue

-

-

-

-158

125

8

9

16

Net cash provided by operating activities

136,117

115,665

60,935

18,391

3,130

-27,376

-37,058

-36,020

Cash flows from investing activities:
Purchases of property and equipment

1,088

298

419

194

17

174

127

151

Proceeds from maturities of marketable securities

182,295

142,655

29,950

0

-

-

-

-

Purchases of marketable securities

299,035

233,124

102,987

0

0

-

-

-

Proceeds from exercise of warrants, net of issuance costs

-

-

-

-

17,088

0

-

-

Proceeds from exercise of stock options, net of issuance costs

-

-

-

-

5,193

1,777

55

289

Net cash provided by (used in) investing activities

-117,828

-90,767

-73,456

-194

-17

-174

-127

-151

Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of options, net of issuance costs

8,419

9,322

7,181

7,683

-

-

-

59,419

Repurchase of common stock

30,975

23,657

0

0

-

-

-

-

Proceeds from issuance of long-term obligation, net of cash paid for issuance costs

-

-

-

-

-

-

-

29,860

Payments related to debt obligation

0

0

15,134

14,779

9,207

4,856

1,025

-

Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercise

6,089

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-28,645

-14,335

-7,953

-7,096

13,074

-3,079

-970

89,568

Supplemental disclosure:
Income taxes paid

6,744

1,351

377

40

57

-

-

-

Net increase in cash and cash equivalents

-10,356

10,563

-20,474

11,101

16,187

-30,629

-38,155

53,397

Supplemental disclosure:
Exercise price of shares tendered in net settlement of cashless option exercise

1,983

0

0

-

-

-

-

-

Recognition of right-of-use asset and lease liability

4,913

-

-

-

-

-

-

-